Additional file 14. Results for bulk data (CD) including DEGs, pathway enrichment analysis, drug targets results, and URs in lesional and non-lesional samples compared to healthy control.
Background: Mesothelioma is an aggressive, fatal cancer that is inextricably linked to asbestos exposure. Recent trials using a combination of the immune checkpoint inhibitors ipilimumab and nivolumab
